22 Jul Skylark Bio
Jodi Cook, CEO
Oct. 6 | 2:45pm | FLW Ballroom G
Cambridge, MA
(Private)
Skylark Bio is a clinical-stage genetic medicine company developing precision, locally delivered gene therapies for monogenic diseases, with the potential to meaningfully improve patient outcomes and quality of life. Its lead program, SKY-GJB2, is being evaluated in SONIX, a Phase 1/2 clinical trial for GJB2-related hearing loss, the leading cause of inherited hearing loss worldwide. Additional programs include SKY-PEN for SLC26A4-related hearing loss (Pendred syndrome) and an undisclosed program in CNS. Skylark’s proprietary gene therapy platform is built on an engineered capsid designed for broad transduction, enabling targeted microdose delivery, cell-specific expression control, and the potential for durable benefit in non-dividing cells. Led by a team with deep expertise in gene therapy and supported by world-class advisors, Skylark is advancing innovative therapies for hearing loss and other genetic disorders that profoundly affect patients and families.